{"id":295339,"date":"2025-04-29T00:00:00","date_gmt":"2025-04-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0021-2021-biopharma-small-cell-lung-cancer-current-treatment-current-treatment-physician\/"},"modified":"2026-04-14T10:12:43","modified_gmt":"2026-04-14T10:12:43","slug":"cutron0021-2025-biopharma-small-cell-lung-cancer-current-treatment-current-treatment-physician-insights-small-cell-lung","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0021-2025-biopharma-small-cell-lung-cancer-current-treatment-current-treatment-physician-insights-small-cell-lung\/","title":{"rendered":"Small Cell Lung Cancer &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Small-Cell Lung Cancer (US)"},"content":{"rendered":"<p>The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. The immune checkpoint inhibitors Tecentriq (Roche; FDA approved in 2019) and Imfinzi (AstraZeneca; 2020) compete for market share in the first-line treatment setting for extensive-stage disease. In September 2024, Tecentriq Hybreza, a subcutaneous formulation of Tecentriq, also entered this space. In the later-line extensive-stage setting, prescribers can choose between the RNA polymerase II inhibitor Zepzelca (PharmaMar; 2020) and, recently, the DLL3-targeting T-cell engager Imdelltra (Amgen; 2024).<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment rates for SCLC in the various stages and lines of therapy?<\/li>\n<li>How are new therapy entrants to the SCLC market performing relative to existing therapies?<\/li>\n<li>What do surveyed physicians consider the main drivers of and key obstacles to the uptake of select therapies?<\/li>\n<li>What are the rates of testing for different biomarkers?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Primary research:<\/strong> Survey of 101 medical oncologists in the United States fielded in February 2025<\/p>\n<p><strong>Key drugs:<\/strong> Tecentriq, Tecentriq Hybreza, Imfinzi, Zepzelca, Imdelltra<\/p>\n","protected":false},"template":"","class_list":["post-295339","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295339\/revisions"}],"predecessor-version":[{"id":575794,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295339\/revisions\/575794"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}